Communiqués Spero Therapeutics, Inc.

Actions

SPRO

US84833T1034

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 17:54:25 28/07/2026			Varia. 5j.	Varia. 1 janv.
1,220 ^USD	+3,39%		-11,96%	-47,85%

27/07	Spero Therapeutics, Inc. annonce la nomination de Debra Jeske Zack au poste de directrice médicale	CI
14/07	Innovent Biologics, Inc. et Spero Therapeutics, Inc. annoncent un accord de licence exclusif pour l'IBI355 (SP001), un anticorps anti-CD40L de troisième génération prêt pour la phase 2	CI

Communiqués

27/07	Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer	AQ
14/07	Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties	AQ
14/07	Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody	AQ
13/05	Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update	AQ
05/05	Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026	AQ
26/03	Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update	AQ
18/03	Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026	AQ
30/01	SEC Enforcement Action Against Former Spero Executives: Individual Liability For Misleading FDA-Related Disclosures	AQ
19/12	Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis	AQ
28/11	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
13/11	Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update	AQ
04/11	Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025	AQ
21/10/25	PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)	AQ
14/10/25	Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek	AQ
12/08/25	Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update	AQ
05/08/25	Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025	AQ
13/05/25	Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update	AQ
05/05/25	Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025	AQ
28/04/25	Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer	AQ
27/03/25	Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update	AQ
18/03/25	Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025	AQ
25/02/25	Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference	AQ
10/01/25	Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes	AQ
14/11/24	Spero Therapeutics : Announces Third Quarter 2024 Operating Results and Provides a Business Update Form 8 K	PU
14/11/24	Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update	AQ